Article
An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics
1 Jan 2021
Abstract excerpt
Next-generation multi-specific antibody therapeutics (MSATs) are engineered to combine several functional activities into one molecule to provide higher efficacy compared to conventional, mono-specific antibody therapeutics. However, highly engineered MSATs frequently display poor yields and less favorable drug-like properties (DLPs), which can adversely affect their development. Systematic screening of a large...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
